Time filter

Source Type

McLean, VA, United States

SAIC Motor Corporation Limited is a Chinese state-owned automotive manufacturing company headquartered in Shanghai, China with multinational operations. One of the "Big Four" Chinese automakers , the company had the largest production volume of any Chinese automaker in 2014 making more than 4.5 million vehicles. Its manufacturing mix is not wholly consumer offerings, however, as many SAIC passenger vehicles are pint-sized commercial vans.SAIC traces its origins to the early years of the Chinese automobile industry in the 1940s, and SAIC was one of the few carmakers in Mao's China, making the Shanghai SH760. Currently, it participates in the oldest surviving Sino-foreign car making joint venture, with Volkswagen, and in addition has had a joint venture with General Motors since 1998. SAIC products sell under a variety of brand names, including those of its joint venture partners. Two notable brands owned by SAIC itself are MG, a historic British car marque, and Roewe, one of the few domestic Chinese luxury car brands. Wikipedia.

Keele B.F.,SAIC
Current Opinion in HIV and AIDS | Year: 2010

PURPOSE OF REVIEW: Improvements in sequencing approaches and robust mathematical modeling have dramatically increased information on viral genetics during acute infection with HIV and simian immunodeficiency virus, providing unprecedented insight into viral transmission and viral/immune interactions. RECENT FINDINGS: Overall viral genetic diversity is reduced significantly during mucosal transmission. Remarkably, in the vast majority of sexual transmissions, this diversity is reduced to a single viral variant that establishes the initial productive clinical infection. By identifying and enumerating transmitted/founder viruses, researchers can begin to define the characteristics that are necessary and sufficient for successful viral replication within a new host. SUMMARY: Acute HIV infection is a critical window of opportunity for vaccine and therapeutic intervention. New sequencing technologies and mathematical modeling of transmission and early evolution have provided a clearer understanding of the number of founder viruses that establish infection, the rapid generation of diversity in these viruses and the subsequent evasion of host immunity. The information gained by identifying transmitted viruses, monitoring the initial host responses to these viruses and then identifying mechanisms of viral escape could provide better strategies for vaccine development, preexposure prophylaxis, microbicides, or other therapeutic interventions. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

After more than three decades since its potential was first recognized, supercritical water oxidation (SCWO) remains an innovative and viable treatment technology for destruction of aqueous based organic wastes. An extensive data base of destruction efficiencies, corrosion data, and salt phase behavior has been developed over the years through the combined efforts of many investigators at both the fundamental research and commercial level. As a result, SCWO technology has been increasingly utilized in a variety of full-scale designs and applications, handling feeds as diverse as polychlorinated biphenyls (PCBs), sewage sludge, spent catalysts, and chemical weapons. This paper reviews the status of current full-scale commercial SCWO facilities around the world, focusing on the unique challenges and design strategies employed by different companies for corrosion and salt precipitation control in each application. A summary of past commercial SCWO activity as well as future plans among the current active SCWO companies is also included. © 2013 Elsevier B.V. All rights reserved. Source

Carrington M.,SAIC | Carrington M.,Massachusetts Institute of Technology | Walker B.D.,Massachusetts Institute of Technology
Annual Review of Medicine | Year: 2012

Host genetic variation is presently estimated to account for about one-fourth of the observed differences in control of HIV across infected individuals. Genome-wide association studies have confirmed that polymorphism within the HLA class I locus is the primary host genetic contributor to determining outcome after infection. Here we progress beyond the genetic associations alone to consider the functional explanations for these correlations. In this process, the complex and multidimensional effects of HLA molecules in viral disease become apparent. © 2012 by Annual Reviews. All rights reserved. Source

Picker L.J.,Oregon Health And Science University | Hansen S.G.,Oregon Health And Science University | Lifson J.D.,SAIC
Annual Review of Medicine | Year: 2012

HIV-1 and its simian counterpart SIV have been exquisitely tailored by evolution to evade host immunity. By virtue of specific adaptations that thwart individual innate or adaptive immune mechanisms, and an overall replication strategy that provides for rapid establishment of a large, systemic viral population, capable of dynamic adaptation to almost all immune selection pressures, these viruses, once established, almost invariably stay one step ahead of the host's immune system, and in the vast majority of infected individuals, replicate indefinitely. Although many vaccine approaches tested to date have been able to enhance the magnitude of the immune responses to HIV/SIV infection, most of these responses, whether cellular or humoral, have largely failed to be both effectively antiviral and targeted to prevent the emergence of fully functional escape variants. Recent advances, however, have provided strong evidence that the initial stages of infection following mucosal transmission of these viruses are more vulnerable to immune intervention, and have led to the development of vaccine strategies that elicit responses able to effectively intervene in these early stages of infection, either preventing acquisition of infection or establishing early, stringent, and durable control. Here, we place HIV/AIDS vaccine development in the context of the basic immunobiology of HIV and SIV, review the evidence for their vulnerability to immune responses immediately after mucosal transmission, and discuss how this newly recognized vulnerability might be exploited for the development of an effective HIV/AIDS vaccine. © 2012 by Annual Reviews. All rights reserved. Source

Biotechnology Advances | Year: 2012

Mammalian cell expression has become the dominant recombinant protein production system for clinical applications because of its capacity for post-translational modification and human protein-like molecular structure assembly. While expression and production have been fully developed and Chinese hamster ovary cells are used for the majority of products both on the market and in clinical development, significant progresses in developing and engineering new cell lines, introducing novel genetic mechanisms in expression, gene silencing, and gene targeting, have been reported in the last several years. With the latest analytical methods development, more attention is being devoted towards product quality including glycol profiling, which leads to better understanding the impact of culture condition during production. Additionally, transient gene expression technology platform plays more important role in biopharmaceutical early development stages. This review focused on the latest advancements in the field, especially in active areas such as expression systems, glycosylation impact factors, and transient gene expression. © 2011 Elsevier Inc. Source

Discover hidden collaborations